Genelux Corp GNLX
We take great care to ensure that the data presented and summarized in this overview for GENELUX CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in GNLX
Top Purchases
Top Sells
About GNLX
Insider Transactions at GNLX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 13
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
33,080
-5.23%
|
$66,160
$2.57 P/Share
|
|
Sep 12
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
31,777
-4.78%
|
$63,554
$2.73 P/Share
|
|
Sep 11
2024
|
James L Tyree |
SELL
Open market or private sale
|
Direct |
1,730
-3.51%
|
$3,460
$2.6 P/Share
|
|
Sep 11
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
31,376
-4.51%
|
$62,752
$2.62 P/Share
|
|
Sep 10
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
20,384
-2.85%
|
$40,768
$2.51 P/Share
|
|
Sep 09
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
23,383
-3.16%
|
$46,766
$2.7 P/Share
|
|
Sep 03
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
42,818
-5.47%
|
$85,636
$2.09 P/Share
|
|
Aug 30
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
142,589
-15.41%
|
$285,178
$2.17 P/Share
|
|
Aug 29
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
107,045
-10.37%
|
$107,045
$1.98 P/Share
|
|
Aug 28
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
15,918
-1.52%
|
$31,836
$2.05 P/Share
|
|
Aug 27
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
51,630
-4.69%
|
$103,260
$2.11 P/Share
|
|
Aug 23
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
40,000
-3.51%
|
$80,000
$2.29 P/Share
|
|
Aug 01
2024
|
John W Smither |
BUY
Grant, award, or other acquisition
|
Direct |
39,541
+42.86%
|
-
|
|
Aug 01
2024
|
John Thomas |
BUY
Grant, award, or other acquisition
|
Direct |
39,541
+7.25%
|
-
|
|
Aug 01
2024
|
Mary Mirabelli |
BUY
Grant, award, or other acquisition
|
Direct |
39,541
+43.19%
|
-
|
|
Aug 01
2024
|
James L Tyree |
BUY
Grant, award, or other acquisition
|
Direct |
39,541
+44.53%
|
-
|
|
Jun 24
2024
|
Caroline Jewett Head of Quality |
SELL
Open market or private sale
|
Direct |
4,961
-23.47%
|
$9,922
$2.12 P/Share
|
|
Jun 24
2024
|
Sean Ryder General Counsel |
SELL
Open market or private sale
|
Direct |
5,496
-22.09%
|
$10,992
$2.12 P/Share
|
|
Jun 24
2024
|
Tony Yu VP, Clinical Trial Operations |
SELL
Open market or private sale
|
Direct |
6,849
-38.66%
|
$13,698
$2.12 P/Share
|
|
May 29
2024
|
Mary Mirabelli |
BUY
Open market or private purchase
|
Direct |
8,000
+39.1%
|
-
|
Last 12 Months Summary
Buy / Acquisition
516K
Shares
From
20
Insiders
| Grant, award, or other acquisition | 248K shares |
|---|---|
| Open market or private purchase | 268K shares |
Sell / Disposition
915K
Shares
From
6
Insiders
| Open market or private sale | 915K shares |
|---|